Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $64M (up 33.7% year over year) with net income of $49M.
Q2 2026 key financials · XBRL
- Revenue
- $64M
- +33.7% YoY · +23.1% QoQ
- Net income
- $49M
- +900.8% YoY · +463.5% QoQ
- Operating margin
- 13.5%
- EPS (diluted)
- $2.30
- +784.6% YoY · +443.3% QoQ
Source: XBRL data from the LIGAND PHARMACEUTICALS INC (LGND) Q2 2026 10-Q on SEC EDGAR. USD.
LIGAND PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $63.7M, up 34% YoY from $47.6M
- Q2 operating margin 13.5% vs 17.7% YoY, with operating expenses at 87% vs 82% of revenue
- Best royalty performer Filspari: $13.6M revenue vs $6.6M; worst Vaxneuvance: $1.4M vs $2.6M
- $700.0M convertible-note financing generated $679.0M net proceeds; $81.7M call spread and approximately $60M share repurchases
- XOMA acquisition funded with cash; management targets approximately $150M-$250M annual royalty-asset deployment
Risk Factors
- New acquisition-integration risk triggered by July 14, 2026 XOMA Acquisition
- XOMA integration risk includes potential failures in financial reporting, internal controls, compliance, and information technology
- Acquisition litigation risk associated with the XOMA Acquisition, though not currently expected to be material
- Royalty buyout risk from counterparties exercising rights below the net present value of future payments
- Debt-service and liquidity risk involving 2030 Notes and 2031 Notes, including potential cash repurchases upon fundamental change
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIGAND PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.